KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Capital Expenditures (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Capital Expenditures for 7 consecutive years, with $733.7 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 47.8% to $733.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Dec 2025, down 32.25% year-over-year, with the annual reading at $1.7 billion for FY2025, 32.25% down from the prior year.
  • Capital Expenditures hit $733.7 million in Q4 2025 for Royalty Pharma, down from $961.9 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.3 billion in Q3 2021 to a low of $85000.0 in Q1 2022.
  • Historically, Capital Expenditures has averaged $512.6 million across 5 years, with a median of $473.8 million in 2023.
  • Biggest five-year swings in Capital Expenditures: crashed 99.98% in 2022 and later skyrocketed 707788.24% in 2023.
  • Year by year, Capital Expenditures stood at $171.7 million in 2021, then soared by 45.71% to $250.2 million in 2022, then soared by 300.51% to $1.0 billion in 2023, then tumbled by 50.47% to $496.4 million in 2024, then soared by 47.8% to $733.7 million in 2025.
  • Business Quant data shows Capital Expenditures for RPRX at $733.7 million in Q4 2025, $961.9 million in Q3 2025, and $1.1 million in Q2 2025.